The ROI of Shifting Mindset From Compliance to Quality
•
0 likes•11 views
Many MedTech companies focus on compliance without considering the importance of quality. In this session, panelists will dive into the differences between compliance vs. quality, the benefits of shifting mindset towards quality, and tips on how to start embedding quality into your organization.
Report
Share
Report
Share
Download to read offline
Recommended
The Compliance Concern: Challenges and Roadblocks for Ensuring Compliance in ...
The medical device industry is doubling down on compliance readiness. This is a significant shift from last year when we saw accelerating product development as the main goal. Ensuring compliance is a requirement for continued success, and most importantly, patient safety. The panelists will discuss the challenges device companies face as they manage compliance throughout the product lifecycle.
How Electronic Data Capture Is Transforming the MedTech Industry
Clinical research is crucial to the life science industry. But did you know that medical device companies require a different approach? In this discussion, our panelists will talk about the challenges of clinical operations for MedTech, the benefits of leveraging MedTech-specific Electronic Data Capture (EDC) systems, the pitfalls of using outdated clinical data collection methods, such as paper, and much more!
Leveraging Modern Software Technologies: MedTech’s Best Kept Secret
There are several moving pieces that influence a medical device company’s time-to-market and continued success. An often overlooked (yet critical) one is the tools used to manage the product lifecycle. Are your tools working for you or slowing down your success? In this session, panelists will discuss trends from the 2023 survey results, common challenges with disjointed software solutions, the impact of modernizing, and the power of a modern QMS.
Behind the Stats: Expectations vs. Reality of Bringing a Device to Market
Learn about what’s currently impacting the broader medical device industry. Our panelists will kick off the week by going over all the trends, statistics, and themes uncovered from the 2023 MedTech Industry Benchmark Survey. The session will uncover major shifts in industry goals, the use of modern Medtech software tools, major gaps in product lifecycle processes, and more. Discover how you can apply these findings as you make decisions within your organization in 2023 and beyond.
Common Misconceptions on Medical Device Risk & Design Controls
Learn about common misconceptions on medical device risk and design controls.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
QMSR Harmonization: The Future of FDA's Quality Management System Regulation
Learn about the future of FDA's Quality Management System regulation.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
QMS from a Regulatory Perspective
Today we will discuss why a QMS is the backbone of Regulatory through the lens of ISO 13845. The presentation will cover the importance of starting a QMS early and ahead of a regulatory strategy.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Modernizing your QMS to keep up with the Modern Age of Requirements
Learn about the importance of a modern QMS to keep up with changing requirements in the MedTech industry.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Recommended
The Compliance Concern: Challenges and Roadblocks for Ensuring Compliance in ...
The medical device industry is doubling down on compliance readiness. This is a significant shift from last year when we saw accelerating product development as the main goal. Ensuring compliance is a requirement for continued success, and most importantly, patient safety. The panelists will discuss the challenges device companies face as they manage compliance throughout the product lifecycle.
How Electronic Data Capture Is Transforming the MedTech Industry
Clinical research is crucial to the life science industry. But did you know that medical device companies require a different approach? In this discussion, our panelists will talk about the challenges of clinical operations for MedTech, the benefits of leveraging MedTech-specific Electronic Data Capture (EDC) systems, the pitfalls of using outdated clinical data collection methods, such as paper, and much more!
Leveraging Modern Software Technologies: MedTech’s Best Kept Secret
There are several moving pieces that influence a medical device company’s time-to-market and continued success. An often overlooked (yet critical) one is the tools used to manage the product lifecycle. Are your tools working for you or slowing down your success? In this session, panelists will discuss trends from the 2023 survey results, common challenges with disjointed software solutions, the impact of modernizing, and the power of a modern QMS.
Behind the Stats: Expectations vs. Reality of Bringing a Device to Market
Learn about what’s currently impacting the broader medical device industry. Our panelists will kick off the week by going over all the trends, statistics, and themes uncovered from the 2023 MedTech Industry Benchmark Survey. The session will uncover major shifts in industry goals, the use of modern Medtech software tools, major gaps in product lifecycle processes, and more. Discover how you can apply these findings as you make decisions within your organization in 2023 and beyond.
Common Misconceptions on Medical Device Risk & Design Controls
Learn about common misconceptions on medical device risk and design controls.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
QMSR Harmonization: The Future of FDA's Quality Management System Regulation
Learn about the future of FDA's Quality Management System regulation.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
QMS from a Regulatory Perspective
Today we will discuss why a QMS is the backbone of Regulatory through the lens of ISO 13845. The presentation will cover the importance of starting a QMS early and ahead of a regulatory strategy.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Modernizing your QMS to keep up with the Modern Age of Requirements
Learn about the importance of a modern QMS to keep up with changing requirements in the MedTech industry.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
eMDR Program and Process
In this session we will learn about the Why, the What, the Who, and the How for Medical Device Reporting to FDA through eMDR Submissions.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Moving up to the State of the Art in Risk Management
During this presentation we will explore where Medical Device Risk Management Systems are today. We will look at the quickly upcoming deadlines for implementing the ISO 14971:2019 3rd Edition, and EN ISO 14971:2019/A11:2021 standards. We will also mention the potential next (4th) edition of ISO 14971, and how the industry may influence the next edition.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
ISO 13485: What's Next?
While ISO 13485 is written in black and white, the alignment between the standard's requirements and expectations is not always clear - especially in regards to SaMD (software as a medical device). This session will discuss aligning ISO 13485 with best practices for SaMD, and how we can expect the shift of the industry to impact the anchor standard of the medical device industry.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Computer Software Assurance (CSA): Understanding the FDA’s New Draft Guidance
Understand the FDA's new draft guidance on Computer Software Assurance (CSA).
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Making Headway Despite the Turbulence: Regulatory Requirements, Quality, and ...
The European Union’s In Vitro Diagnostic Medical Devices Regulation, or IVDR, became effective May 26, 2022. In this session, you’ll get a glimpse of what’s changed since implementation day, the latest guidance available, and ways to keep your IVDD to IVDR transition moving forward.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Reducing Friction Between Companies and Regulatory Bodies
We are operating in a complex environment, which is still undergoing changes. A lack of regulatory/quality management resources can be seen on both notified bodies and the industry. To overcome these hurdles, close collaboration and communication between companies and the notified body is necessary.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Latin American Regulations - What you Don't Know
Central and South America are emerging as hot new Medical Device markets. These two subject matter experts in the area break down everything from regulatory advantages and ethical dilemmas.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Insights on the MedTech Regulatory and Clinical Environment in Israel
Facts about the high-tech industry of Israel
The new medical device law in Israel
The regulatory landscape - requirements and market access
Performing clinical trials in Israel
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
The Global Guide to Human Factors and Usability Engineering Regulations
The regulatory landscape related to human factors and usability engineering has continued to evolve since FDA issued its draft guidance for human factors over ten years ago. In fact, the international standard for usability engineering, IEC 62366-1: 2015 was amended as recently as 2020. The good news is that the pathway to a successful regulatory strategy, in terms of human factors and usability engineering, has never been more clear. The regulators have spoken, by way of guidance and standards documents, all that is left to do is to make sense of it all as it relates to your specific device or product.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
MDSAP Certification: Success and Failures
Join industry expert, Danny Kroo, key takeaways from the session include: 1. What is MDSAP and when should you consider it? 2. How to prepare for an MDSAP certification audit 3. What are common nonconformities issued by auditing organizations
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
QMSR Harmonization - The Good the Bad and the Ugly
Learn about the proposed QMSR rule, intended benefits of MDSAP for the regulatory authorities, benefits for the manufacturer, and similarities between ISO 13485 and FDA Regulations, and more!
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
UDI - US vs EU: What You Need to Know
Unique Device Identification —aka UDI— is about more than barcodes and regulatory red tape. This global system for identifying medical devices is a chance to radically improve the quality of life for patients, providers, and producers of medical devices. However, implementing UDI into your product lifecycle means navigating differing requirements in both the United States and the European Union. If you’re looking to go global, we’ve brought together three industry leaders on the subject to make sure you know the difference.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
State of Swexit/Brexit
The EU has and will continue to change dramatically over the coming years…In this session, two EU regulatory experts unpack the implications that Britain and Switzerland leaving the EU will have from a regulatory standpoint.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Designing an International Regulatory Strategy: Why do so many get it wrong?
What is Regulatory Strategy?
Why is Regulatory Strategy important?
What is International Regulatory Strategy?
Why is International Regulatory Strategy important?
How early in the product development lifecycle should we consider international regulatory strategy?
What’s the relationship between International Regulatory Strategy and International Reimbursement Strategy?
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Implementing a Global Unique Device Identification (UDI) Solution: Regional U...
UDI data requirement experts Gary Saner and John Lorenc of Reed Tech will discuss best practices for UDI preparations and the future potential impacts to medical device manufacturers as global health authorities publish mandates.
This session will give suggested best practices concerning EU EUDAMED preparation, what we have learned via testing and a Q&A session. Bring your specific questions concerning medical device registration scenarios, data elements and requirements. The speakers will review and provide clarity on currently posted guidance and answer your questions concerning EUDAMED and other health authority timelines.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
Software as a Medical Device (SaMD) Challenges and Opportunities for 2021 and...
The SARS-CoV-2 pandemic drastically changes the landscape of digital health innovation. The FDA authorized emergency use for a variety of SaMD products including but not limited to mental health, clinical decision support and remote monitoring software applications. In addition, FDA recently launched the Digital Health Center of Excellence, provided updates on the pre-certification program, and host a session to convey FDA’s current thinking on AI/ML SaMD validation.
SaMD manufacturers must keep up with the fast-evolving regulatory landscape and optimize their software development practices with a goal to demonstrate conformance to the QMS requirements effectively and efficiently.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
A Delay in MDR: Where are We Now
With the COVID-19 crisis, the Medical Device Regulations (MDR) have been pushed back one year, this delay has given a respite for those companies that were not quite ready for the increase regulations.
In this session, we will be discussing the current status of the medical device industry regarding MDR and what are others doing to get ready.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
FDA's 510(k) Modernization: What if Anything has Changed? Is Changing? Will C...
FDA caused quite a stir when it announced transformative changes to modernize its 510(k) program to improve the safety and effectiveness of medical devices.
But as we all know, the more things change, the more they stay the same. If you dive deep into FDA’s statement, you’ll realize that there’s probably not a lot that’s different.
In this session, Michael Drues, Ph.D., President of Vascular Sciences, will share what FDA's 510(k) Modernization means, any evidence that changes are happening, and what medical device manufactures need to know about 510k modernization.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
Audits: Let’s get back to Auditing, REMOTELY!
Audits are a fact of life in the medtech industry, whether internal audits, supplier audits, or notified body audits. While previously most audits were conducted on-site and in person, the industry has had to pivot to remote auditing wherever possible.
In this session, Cannon Quality Group founder/CEO Nicolle Cannon will share CQG’s experiences as an early adopter of remote auditing. CQG has conducted numerous internal and supplier audits remotely as well as supported clients undergoing remote notified body audits.
The presentation will cover both the hard skills of getting comfortable with various technology platforms as well as the soft skills of effective communication between auditor and auditee. Many now predict remote auditing will remain the default option in the coming years.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
Impact of Brexit, Swixit, Turkxit for the European Medical Device Market
The European Union is in transition now due to some regulatory changes. EU MDR will be applicable by May 26th, 2021, but in the meantime, other political situations may impact this timeline.
Manufacturers that would like to register their product in Europe need to understand the potential situations that could happen and how this can change your regulatory strategy.
Brexit will apply by January 1st, 2021. Swixit and Turkxit will depend on the EU commission, but this may happen by May 26th, 2021.
This presentation takes a deep dive into the implications of Brexit, Swixit, Turkxit for the European Medical Device Market.
This free in-depth webinar, presented by Monir El Azzouzi , Founder of Easy Medical Device, will cover the current (Winter 2020) Brexit, Swixit, and Turkxit situation for the European Medical Device Market.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
More Related Content
More from Greenlight Guru
eMDR Program and Process
In this session we will learn about the Why, the What, the Who, and the How for Medical Device Reporting to FDA through eMDR Submissions.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Moving up to the State of the Art in Risk Management
During this presentation we will explore where Medical Device Risk Management Systems are today. We will look at the quickly upcoming deadlines for implementing the ISO 14971:2019 3rd Edition, and EN ISO 14971:2019/A11:2021 standards. We will also mention the potential next (4th) edition of ISO 14971, and how the industry may influence the next edition.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
ISO 13485: What's Next?
While ISO 13485 is written in black and white, the alignment between the standard's requirements and expectations is not always clear - especially in regards to SaMD (software as a medical device). This session will discuss aligning ISO 13485 with best practices for SaMD, and how we can expect the shift of the industry to impact the anchor standard of the medical device industry.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Computer Software Assurance (CSA): Understanding the FDA’s New Draft Guidance
Understand the FDA's new draft guidance on Computer Software Assurance (CSA).
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Making Headway Despite the Turbulence: Regulatory Requirements, Quality, and ...
The European Union’s In Vitro Diagnostic Medical Devices Regulation, or IVDR, became effective May 26, 2022. In this session, you’ll get a glimpse of what’s changed since implementation day, the latest guidance available, and ways to keep your IVDD to IVDR transition moving forward.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Reducing Friction Between Companies and Regulatory Bodies
We are operating in a complex environment, which is still undergoing changes. A lack of regulatory/quality management resources can be seen on both notified bodies and the industry. To overcome these hurdles, close collaboration and communication between companies and the notified body is necessary.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Latin American Regulations - What you Don't Know
Central and South America are emerging as hot new Medical Device markets. These two subject matter experts in the area break down everything from regulatory advantages and ethical dilemmas.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Insights on the MedTech Regulatory and Clinical Environment in Israel
Facts about the high-tech industry of Israel
The new medical device law in Israel
The regulatory landscape - requirements and market access
Performing clinical trials in Israel
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
The Global Guide to Human Factors and Usability Engineering Regulations
The regulatory landscape related to human factors and usability engineering has continued to evolve since FDA issued its draft guidance for human factors over ten years ago. In fact, the international standard for usability engineering, IEC 62366-1: 2015 was amended as recently as 2020. The good news is that the pathway to a successful regulatory strategy, in terms of human factors and usability engineering, has never been more clear. The regulators have spoken, by way of guidance and standards documents, all that is left to do is to make sense of it all as it relates to your specific device or product.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
MDSAP Certification: Success and Failures
Join industry expert, Danny Kroo, key takeaways from the session include: 1. What is MDSAP and when should you consider it? 2. How to prepare for an MDSAP certification audit 3. What are common nonconformities issued by auditing organizations
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
QMSR Harmonization - The Good the Bad and the Ugly
Learn about the proposed QMSR rule, intended benefits of MDSAP for the regulatory authorities, benefits for the manufacturer, and similarities between ISO 13485 and FDA Regulations, and more!
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
UDI - US vs EU: What You Need to Know
Unique Device Identification —aka UDI— is about more than barcodes and regulatory red tape. This global system for identifying medical devices is a chance to radically improve the quality of life for patients, providers, and producers of medical devices. However, implementing UDI into your product lifecycle means navigating differing requirements in both the United States and the European Union. If you’re looking to go global, we’ve brought together three industry leaders on the subject to make sure you know the difference.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
State of Swexit/Brexit
The EU has and will continue to change dramatically over the coming years…In this session, two EU regulatory experts unpack the implications that Britain and Switzerland leaving the EU will have from a regulatory standpoint.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Designing an International Regulatory Strategy: Why do so many get it wrong?
What is Regulatory Strategy?
Why is Regulatory Strategy important?
What is International Regulatory Strategy?
Why is International Regulatory Strategy important?
How early in the product development lifecycle should we consider international regulatory strategy?
What’s the relationship between International Regulatory Strategy and International Reimbursement Strategy?
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Implementing a Global Unique Device Identification (UDI) Solution: Regional U...
UDI data requirement experts Gary Saner and John Lorenc of Reed Tech will discuss best practices for UDI preparations and the future potential impacts to medical device manufacturers as global health authorities publish mandates.
This session will give suggested best practices concerning EU EUDAMED preparation, what we have learned via testing and a Q&A session. Bring your specific questions concerning medical device registration scenarios, data elements and requirements. The speakers will review and provide clarity on currently posted guidance and answer your questions concerning EUDAMED and other health authority timelines.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
Software as a Medical Device (SaMD) Challenges and Opportunities for 2021 and...
The SARS-CoV-2 pandemic drastically changes the landscape of digital health innovation. The FDA authorized emergency use for a variety of SaMD products including but not limited to mental health, clinical decision support and remote monitoring software applications. In addition, FDA recently launched the Digital Health Center of Excellence, provided updates on the pre-certification program, and host a session to convey FDA’s current thinking on AI/ML SaMD validation.
SaMD manufacturers must keep up with the fast-evolving regulatory landscape and optimize their software development practices with a goal to demonstrate conformance to the QMS requirements effectively and efficiently.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
A Delay in MDR: Where are We Now
With the COVID-19 crisis, the Medical Device Regulations (MDR) have been pushed back one year, this delay has given a respite for those companies that were not quite ready for the increase regulations.
In this session, we will be discussing the current status of the medical device industry regarding MDR and what are others doing to get ready.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
FDA's 510(k) Modernization: What if Anything has Changed? Is Changing? Will C...
FDA caused quite a stir when it announced transformative changes to modernize its 510(k) program to improve the safety and effectiveness of medical devices.
But as we all know, the more things change, the more they stay the same. If you dive deep into FDA’s statement, you’ll realize that there’s probably not a lot that’s different.
In this session, Michael Drues, Ph.D., President of Vascular Sciences, will share what FDA's 510(k) Modernization means, any evidence that changes are happening, and what medical device manufactures need to know about 510k modernization.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
Audits: Let’s get back to Auditing, REMOTELY!
Audits are a fact of life in the medtech industry, whether internal audits, supplier audits, or notified body audits. While previously most audits were conducted on-site and in person, the industry has had to pivot to remote auditing wherever possible.
In this session, Cannon Quality Group founder/CEO Nicolle Cannon will share CQG’s experiences as an early adopter of remote auditing. CQG has conducted numerous internal and supplier audits remotely as well as supported clients undergoing remote notified body audits.
The presentation will cover both the hard skills of getting comfortable with various technology platforms as well as the soft skills of effective communication between auditor and auditee. Many now predict remote auditing will remain the default option in the coming years.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
Impact of Brexit, Swixit, Turkxit for the European Medical Device Market
The European Union is in transition now due to some regulatory changes. EU MDR will be applicable by May 26th, 2021, but in the meantime, other political situations may impact this timeline.
Manufacturers that would like to register their product in Europe need to understand the potential situations that could happen and how this can change your regulatory strategy.
Brexit will apply by January 1st, 2021. Swixit and Turkxit will depend on the EU commission, but this may happen by May 26th, 2021.
This presentation takes a deep dive into the implications of Brexit, Swixit, Turkxit for the European Medical Device Market.
This free in-depth webinar, presented by Monir El Azzouzi , Founder of Easy Medical Device, will cover the current (Winter 2020) Brexit, Swixit, and Turkxit situation for the European Medical Device Market.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
More from Greenlight Guru (20)
Moving up to the State of the Art in Risk Management
Moving up to the State of the Art in Risk Management
Computer Software Assurance (CSA): Understanding the FDA’s New Draft Guidance
Computer Software Assurance (CSA): Understanding the FDA’s New Draft Guidance
Making Headway Despite the Turbulence: Regulatory Requirements, Quality, and ...
Making Headway Despite the Turbulence: Regulatory Requirements, Quality, and ...
Reducing Friction Between Companies and Regulatory Bodies
Reducing Friction Between Companies and Regulatory Bodies
Insights on the MedTech Regulatory and Clinical Environment in Israel
Insights on the MedTech Regulatory and Clinical Environment in Israel
The Global Guide to Human Factors and Usability Engineering Regulations
The Global Guide to Human Factors and Usability Engineering Regulations
QMSR Harmonization - The Good the Bad and the Ugly
QMSR Harmonization - The Good the Bad and the Ugly
Designing an International Regulatory Strategy: Why do so many get it wrong?
Designing an International Regulatory Strategy: Why do so many get it wrong?
Implementing a Global Unique Device Identification (UDI) Solution: Regional U...
Implementing a Global Unique Device Identification (UDI) Solution: Regional U...
Software as a Medical Device (SaMD) Challenges and Opportunities for 2021 and...
Software as a Medical Device (SaMD) Challenges and Opportunities for 2021 and...
FDA's 510(k) Modernization: What if Anything has Changed? Is Changing? Will C...
FDA's 510(k) Modernization: What if Anything has Changed? Is Changing? Will C...
Impact of Brexit, Swixit, Turkxit for the European Medical Device Market
Impact of Brexit, Swixit, Turkxit for the European Medical Device Market
Recently uploaded
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Physiology of Chemical Sensation of smell.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With 100% Satisfaction
micro teaching on communication m.sc nursing.pdf
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Valuable Content of Human Anatomy and Physiology of Urinary system as per PCI Syllabus for Pharmacy and PharmD Students.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Antiulcer drugs Advance Pharmacology .pptx
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Prix Galien International 2024 Forum Program
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Christopher Hearon
The University of Texas Southwestern Medical Center
Are There Any Natural Remedies To Treat Syphilis.pdf
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Recently uploaded (20)
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
The ROI of Shifting Mindset From Compliance to Quality
- 1. 2023 MedTech Industry Report The ROI of Shifting Mindset From Compliance to Quality